Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes

This study will be an online survey experiment conducted with adults who smoke cigarettes (ages 21+) to examine their reactions to modified risk advertising claims authorized by the Food \& Drug Administration (FDA) for two smokeless tobacco brands (General Snus and Copenhagen), which describe the lower risks of these products compared to cigarette smoking. The study will compare effects of ads with different two different claim types (i.e. claims about reduced lung cancer risk and claims about reduced risks for multiple disease) versus ads with no reduced-risk claims, and examine effects on message and product perceptions, and interest in using the smokeless tobacco products. This study will also examine how smokers' reactions/interest may vary based on the product brand, and asses prior awareness/exposure to the authorized claims.

NCT Number	NCT06927700
Lead Sponsor	Rutgers, The State University of New Jersey Collaborators: National Cancer Institute (NCI)
Conditions	Tobacco Product Beliefs and Use
Enrollment	1,257 participants
Start Date	2025-04-24
Primary Completion	2025-05-04 (estimated)
Study Completion	2025-05-04 (estimated)
Updated on ClinicalTrials.gov	2026-03-04